QGEN Collaborates With McGill University Centre: Stock to Gain?

Zacks11-14

QIAGEN N.V. QGEN recently collaborated with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further advance...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483583022?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","is_english":true,"pubTime":"2024-11-14 00:18","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483583022","market":"us","top_or_hot":-1,"title":"QGEN Collaborates With McGill University Centre: Stock to Gain?","media":"Zacks","content":"<div>\n<p>QIAGEN N.V. QGEN recently collaborated with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further advance...</p>\n\n<a href=\"https://finance.yahoo.com/news/qgen-collaborates-mcgill-university-centre-161800594.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QGEN Collaborates With McGill University Centre: Stock to Gain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQGEN Collaborates With McGill University Centre: Stock to Gain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 00:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/qgen-collaborates-mcgill-university-centre-161800594.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN recently collaborated with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further advance...</p>\n\n<a href=\"https://finance.yahoo.com/news/qgen-collaborates-mcgill-university-centre-161800594.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"https://finance.yahoo.com/news/qgen-collaborates-mcgill-university-centre-161800594.html","article_id":"2483583022","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483583022","pubTimestamp":1731514680,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"QIAGEN N.V. QGEN recently collaborated with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further advance microbiome sciences and focus on key areas such as DNA extraction from low microbial biomass samples and anaerobic culturing protocols.The latest partnership aims to strengthen QIAGEN’s microbiome research efforts while supporting innovation at the McGill Centre.The latest collaboration is expected to strengthen QIAGEN’s presence in microbiome research space across North America, which represents a $1.8 billion market. It will also help gain a deeper understanding of the needs of the scientific community for studying the function of vast microbial ecosystems. The collaboration aims to enhance QIAGEN’s ability to develop new microbiome solutions based on customer feedback and support the scientific community in uncovering new insights into the microbiome’s impact on health and dise","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","BK4567":"ESG概念","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4082":"医疗保健设备","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","BK4121":"生命科学工具和服务","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","BK4588":"碎股","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","RMD":"瑞思迈","QGEN":"快而精医药","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0238689110.USD":"贝莱德环球动力股票基金","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","GMED":"Globus Medical Inc","BK4581":"高盛持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","RMD.AU":"Resmed DRC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD"},"translate_title":"QGEN与麦吉尔大学中心合作：股票收益？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"QGEN":1,"BSX":1,"GMED":1,"RMD.AU":0.9},"content_text":"QIAGEN N.V. QGEN recently collaborated with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further advance microbiome sciences and focus on key areas such as DNA extraction from low microbial biomass samples and anaerobic culturing protocols.\nThe latest partnership aims to strengthen QIAGEN’s microbiome research efforts while supporting innovation at the McGill Centre. \nQGEN Stock’s Trend Following the News\nSubsequent to the news, the share price of QGEN remained unchanged at $43.23 in after-market trading yesterday. The company is gaining synergies from its collaboration in the microbiome research space. Earlier this year, QGEN partnered with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. Henceforth, we expect the latest partnership with McGill Centre to motivate market sentiment in favor of QGEN in the coming days.\nQIAGEN currently has a market capitalization of $9.83 billion. The company delivered an average earnings surprise of 2.6% in the trailing four quarters.\nDetails of the Collaboration \nThe company will support the McGill Centre with reagents for research across a variety of microbiology and genomic processing workflows and contribute to joint research projects, which will demonstrate the suitability of QIAGEN products for microbiome science. The collaboration will also enable the McGill Centre to train the next generation of scientists better and make microbiome research accessible to a wider range of scientific domains. \nQIAGEN products will be used in the McGill Centre's experimental platforms. The centre will also function as a beta-testing site for developing new QIAGEN products for microbiome applications, and refining and optimizing these for broader applications in the scientific community.\nThe center aims to integrate and synergize microbiome research activities by offering services through two distinct yet complementary experimental platforms — Gnotobiotic Animal Research and Microbial Services. \nSignificance of QIAGEN’s Collaboration\nMicrobiome research aims to explore the relationships between microorganisms such as bacteria, fungi and viruses, and their hosts. It can help better understand the microbiome’s impact on health, disease, and microbial ecological processes to develop novel diagnostic and therapeutic strategies. \nThe latest collaboration is expected to strengthen QIAGEN’s presence in microbiome research space across North America, which represents a $1.8 billion market. It will also help gain a deeper understanding of the needs of the scientific community for studying the function of vast microbial ecosystems. The collaboration aims to enhance QIAGEN’s ability to develop new microbiome solutions based on customer feedback and support the scientific community in uncovering new insights into the microbiome’s impact on health and disease.\nImage Source: Zacks Investment Research\nIndustry Prospects Favor QIAGEN\nAccording to a Research Nester report, the human microbiome market is projected to grow by more than $117.3 billion by 2037, experiencing a compound annual growth rate of 32.2% during 2024-2037. Key factors influencing the market growth include rising cases of lifestyle-related diseases like diabetes and increasing investment in biological drug development across the globe. \nQIAGEN’s Recent Development\nQIAGEN recently achieved FDA clearance for its QIAstat-Dx Respiratory Panel Mini test for clinical use. This is the second QIAstat-Dx respiratory panel to receive a U.S. regulatory nod this year.\nQGEN Stock Price Performance\nYear to date, QGEN’s shares have risen 6% compared with the industry’s 10.7% growth.\nQGEN’s Zacks Rank and Key Picks\nThe company currently carries a Zacks Rank #3 (Buy).\nSome better-ranked stocks in the broader medical space are Boston Scientific BSX, Globus Medical GMED and ResMed RMD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nBoston Scientific’s shares have surged 58.3% in the past year. Estimates for the company’s earnings per share (EPS) have jumped 2.5% to $2.46 for 2024 and 0.4% to $2.72 for 2025 in the past 30 days. BSX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average beat of 8.3%. In the last reported quarter, it posted an earnings surprise of 8.6%.\nEstimates for Globus Medical’s 2024 EPS have remained constant at $2.84 in the past 30 days. Shares of the company have surged 61% in the past year compared with the industry’s growth of 24.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 12.1%. In the last reported quarter, it delivered an earnings surprise of 10.3%.\nEstimates for ResMed’s fiscal 2025 EPS have risen 2.2% to $9.22 in the past 30 days. Shares of the company have surged 58.8% in the past year compared with the industry’s 29.2% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nQIAGEN N.V. (QGEN) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483583022"}